Merck's new cholesterol pill targets blockbuster status
The FDA approval of Merck's novel cholesterol drug, Lipfendra, positions the company to capture a significant market share in cardiovascular treatment.
The argument
The drug is designed to lower bad cholesterol by up to 60% when combined with statins. Analysts project peak annual sales for Lipfendra to exceed $5 billion.
The thesis, stress-tested
✓ What validates it
- ✓Initial quarterly sales figures for Lipfendra exceeding market expectations
- ✓Positive data releases from clinical trials evaluating cardiovascular outcomes
▸ Risks discussed
- ▸Failure to demonstrate that the drug successfully prevents heart attacks and strokes in ongoing studies
- ▸Insurers refusing coverage or demanding high copays for the new treatment
Hear it yourself
"The drug is from The US pharma company Merck. It's called Lipfendra, and it's designed to help lower cholesterol levels beyond what statins alone can do. Studies show that liphendra cuts bad cholesterol by up to 60%, and Merck is now looking at whether the drug can also prevent heart attacks and strokes."
00:00 / 00:19
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE